Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer

被引：7

作者：

Nagata, Yujiro ^{[1
]}

Matsukawa, Takuo ^{[1
]}

Tomisaki, Ikko ^{[1
]}

Fujimoto, Naohiro ^{[1
]}

机构：

[1] Univ Occupat & Environm Hlth, Dept Urol, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 02期

关键词：

Prostate cancer; hormone-sensitive; androgen-deprivation therapy; survival; prostate-specific antigen; PSA NADIR; SURVIVAL; DOCETAXEL; EFFICACY; SAFETY; OLDER; TIME;

D O I：

10.21873/anticanres.15573

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: We examined the prognostic use of the 3-month prostate-specific antigen (PSA3m) level after androgen-deprivation therapy in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Patients and Methods: The present study included 145 patients with mHSPC who received primary androgen deprivation therapy. Results: The optimal cutoff PSA3m value for prediction of 5-year overall survival was 2.56 ng/ml (area under the receiver operating characteristics curve=0.67) using a time-dependent receiver operating characteristic (survival ROC) curve. In patients with CHAARTED low-volume and LATITUDE low-risk disease, the median overall survival was longer for patients with low PSA3m than that for those with high PSA3m. Multivariate analysis revealed PSA3m (hazard ratio=1.99; p=0.006) and age >= 80 years as independent risk factors for overall survival in patients with mHSPC. Conclusion: PSA3m can be a useful prognostic biomarker to avoid excessive upfront combination therapy, particularly in elderly patients with low-volume and low-risk mHSPC.

引用

页码：1107 / 1114

页数：8

共 29 条

[1] Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival [J].

Akaza, Hideyuki ;

Hinotsu, Shiro ;

Usami, Michiyuki ;

Arai, Yoichi ;

Kanetake, Hiroshi ;

Naito, Seiji ;

Hirao, Yoshihiko .

CANCER, 2009, 115 (15) :3437-3445

[2] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].

Armstrong, Andrew J. ;

Szmulewitz, Russell Z. ;

Petrylak, Daniel P. ;

Holzbeierlein, Jeffrey ;

Villers, Arnauld ;

Azad, Arun ;

Alcaraz, Antonio ;

Alekseev, Boris ;

Iguchi, Taro ;

Shore, Neal D. ;

Rosbrook, Brad ;

Sugg, Jennifer ;

Baron, Benoit ;

Chen, Lucy ;

Stenzl, Arnulf .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+

[3] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer [J].

Chi, Kim N. ;

Agarwal, Neeraj ;

Bjartell, Anders ;

Chung, Byung Ha ;

Pereira de Santana Gomes, Andrea J. ;

Given, Robert ;

Juarez Soto, Alvaro ;

Merseburger, Axel S. ;

Ozguroglu, Mustafa ;

Uemura, Hirotsugu ;

Ye, Dingwei ;

Deprince, Kris ;

Naini, Vahid ;

Li, Jinhui ;

Cheng, Shinta ;

Yu, Margaret K. ;

Zhang, Ke ;

Larsen, Julie S. ;

McCarthy, Sharon ;

Chowdhury, Simon .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) :13-24

[4]

Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI [10.1016/j.annonc.2020.01.002, 10.1093/annonc/mdz396]

[5] EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer [J].

Cornford, Philip ;

van den Bergh, Roderick C. N. ;

Briers, Erik ;

Van den Broeck, Thomas ;

Cumberbatch, Marcus G. ;

De Santis, Maria ;

Fanti, Stefano ;

Fossati, Nicola ;

Gandaglia, Giorgio ;

Gillessen, Silke ;

Grivas, Nikolaos ;

Grummet, Jeremy ;

Henry, Ann M. ;

van der Kwast, Theodorus H. ;

Lam, Thomas B. ;

Lardas, Michael ;

Liew, Matthew ;

Mason, Malcolm D. ;

Moris, Lisa ;

Oprea-Lager, Daniela E. ;

van der Poel, Henk G. ;

Rouviere, Olivier ;

Schoots, Ivo G. ;

Tilki, Derya ;

Wiegel, Thomas ;

Willemse, Peter-Paul M. ;

Mottet, Nicolas .

EUROPEAN UROLOGY, 2021, 79 (02) :263-282

[6] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J].

Davis, Ian D. ;

Martin, Andrew J. ;

Stockler, Martin R. ;

Begbie, Stephen ;

Chi, Kim N. ;

Chowdhury, Simon ;

Coskinas, Xanthi ;

Frydenberg, Mark ;

Hague, Wendy E. ;

Horvath, Lisa G. ;

Joshua, Anthony M. ;

Lawrence, Nicola J. ;

Marx, Gavin ;

McCaffrey, John ;

McDermott, Ray ;

McJannett, Margaret ;

North, Scott A. ;

Parnis, Francis ;

Parulekar, Wendy ;

Pook, David W. ;

Reaume, M. Neil ;

Sandhu, Shahneen K. ;

Tan, Alvin ;

Tan, T. Hsiang ;

Thomson, Alastair ;

Tu, Emily ;

Vera-Badillo, Francisco ;

Williams, Scott G. ;

Yip, Sonia ;

Zhang, Alison Y. ;

Zielinski, Robert R. ;

Sweeney, Christopher J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :121-131

[7] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

Sulur, Giri ;

Luna, Yesenia ;

Li, Susan ;

Mundle, Suneel ;

Chi, Kim N. .

LANCET ONCOLOGY, 2019, 20 (05) :686-700

[8] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

De Porre, Peter ;

Kheoh, Thian ;

Park, Youn C. ;

Todd, Mary B. ;

Chi, Kim N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360

[9] Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer [J].

Fujimoto, Naohiro ;

Shiota, Masaki ;

Matsukawa, Takuo ;

Minato, Akinori ;

Tomisaki, Ikko ;

Ohnishi, Rei ;

Eto, Masatoshi .

IN VIVO, 2021, 35 (02) :1101-1108

[10] Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL [J].

Graff, J. N. ;

Baciarello, G. ;

Armstrong, A. J. ;

Higano, C. S. ;

Iversen, P. ;

Flaig, T. W. ;

Forer, D. ;

Parli, T. ;

Phung, D. ;

Tombal, B. ;

Beer, T. M. ;

Sternberg, C. N. .

ANNALS OF ONCOLOGY, 2016, 27 (02) :286-294

← 1 2 3 →